|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for TAB2 |
 Gene summary |
| Basic gene Info. | Gene symbol | TAB2 |
| Gene name | TGF-beta activated kinase 1/MAP3K7 binding protein 2 | |
| Synonyms | CHTD2|MAP3K7IP2|TAB-2 | |
| Cytomap | UCSC genome browser: 6q25.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001292034.2, NM_001292035.2,NM_015093.5,NR_125861.1,NM_145342.1, | |
| Description | TAK1-binding protein 2TGF-beta-activated kinase 1 and MAP3K7-binding protein 2mitogen-activated protein kinase kinase kinase 7-interacting protein 2 | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 605101 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000055208 | ||
| HPRD : 05483 | ||
| Vega : OTTHUMG00000015783 | ||
| Protein | UniProt: Q9NYJ8 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_TAB2 | |
| BioGPS: 23118 | ||
| Pathway | NCI Pathway Interaction Database: TAB2 | |
| KEGG: TAB2 | ||
| REACTOME: TAB2 | ||
| Pathway Commons: TAB2 | ||
| Context | iHOP: TAB2 | |
| ligand binding site mutation search in PubMed: TAB2 | ||
| UCL Cancer Institute: TAB2 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0045860 | positive regulation of protein kinase activity | 11460167 |
| Top |
| Ligand binding site mutations for TAB2 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | C687 | E688D | BLCA | 1 | C684 | R683C | COAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for TAB2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | C687 | E688D | -0.9983445 | C684 | R683C | -0.81101334 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for TAB2 from PDB |
| Top |
| Differential gene expression and gene-gene network for TAB2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for TAB2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C3554279 | CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 2 | 1 | GeneticVariation |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for TAB2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of TAB2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ZN | ZINC(2+) | 2wwz | C | C684 C687 | ZN | ZINC(2+) | 2wx0 | C | C684 C687 | ZN | ZINC(2+) | 2wx0 | G | C684 C687 | ZN | ZINC(2+) | 2wx1 | C | C684 C687 |
| Top |
| Conservation information for LBS of TAB2 |
| Multiple alignments for Q9NYJ8 in multiple species |
| LBS | AA sequence | # species | Species | A672 | QWNCTACTFLN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | C670 | GAQWNCTACTF | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | C673 | WNCTACTFLNH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | C684 | PALIRCEQCEM | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | C687 | IRCEQCEMPRH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |